Trial Profile
NICO - CA209-891: Neoadjuvant and adjuvant nivolumab as Immune Checkpoint inhibition in Oral cavity cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2023
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Cisplatin
- Indications Head and neck cancer; Mouth neoplasm; Salivary gland cancer; Squamous cell cancer; Tongue cancer
- Focus Therapeutic Use
- Acronyms NICO
- 11 Jan 2021 Status changed from active, no longer recruiting to discontinued.
- 11 Jan 2021 Status changed from active, no longer recruiting to discontinued.
- 04 Jan 2021 Status changed from recruiting to active, no longer recruiting.